Press Release

RepliCel Receives European Patent for its Innovative Dermal Injector Technology

8 years ago Jan 10, 2016

RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic...

RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement

8 years ago Dec 22, 2015

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin

8 years ago Dec 16, 2015

Phase 1 clinical trial investigating the use of a patient-specific cell-based dermal rejuvenation product (RCS-01)...

RepliCel Life Sciences Announces Leadership Transition

8 years ago Dec 15, 2015

Lee Buckler, former VP Business & Corporate Development, appointed CEO President & Director; David Hall...

RepliCel Life Sciences Inc. Announces Closing of First Tranche of Private Placement

8 years ago Nov 22, 2015

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

First Participants Enrolled in RepliCel’s Phase 1 Clinical Trial of its RCS-01 Dermatology Injectable

8 years ago Oct 19, 2015

Testing the use of a cell-based injectable as a regenerative alternative for the global dermal...

RepliCel Life Sciences Inc. Announces Brokered Private Placement

8 years ago Oct 19, 2015

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FORDISSEMINATION IN THE UNITED STATES...

Industry Leader Geoff MacKay Joins RepliCel Life Sciences’ Board of Directors

8 years ago Oct 14, 2015

VANCOUVER, BC – October 15, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP),...

RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study

9 years ago Sep 14, 2015

Clinical trial site located at IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in GermanyVANCOUVER, BC –...

RepliCel Life Sciences Cleared to Initiate Clinical Trial of RCS-01 for Dermal Rejuvenation

9 years ago Sep 04, 2015

Patient recruitment will take place at the IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany...

RepliCel Reports Second Quarter 2015 Financial Results

9 years ago Aug 27, 2015

VANCOUVER, BC – August 28, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP),...

RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype

9 years ago Jul 28, 2015

Novel features of next-generation design promise to serve and expand the dermal injectable marketVANCOUVER, BC...

RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial

9 years ago Jul 20, 2015

German-based trial to test RCS-01 cell therapy treatment for aged and sun-damaged skin VANCOUVER, BC...

RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis

9 years ago Jun 29, 2015

ReaCT Trial at University of British Columbia Treating Patients with Autologous CellTherapyVANCOUVER, BC – June...

RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement

9 years ago Jun 25, 2015

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

RepliCel Life Sciences Announces Brokered Private Placement

9 years ago May 31, 2015

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

Events,Press Release

RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum

9 years ago May 06, 2015

Unique forum brings together leading family offices and foundations seeking impactful investment and philanthropic opportunities...

RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results

9 years ago Apr 28, 2015

VANCOUVER, BC – April 29, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP),...

RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis

9 years ago Apr 14, 2015

The University of British Columbia Clinical Research Ethics Board Clears Clinical Trial to Proceed with...

RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates

9 years ago Apr 06, 2015

VANCOUVER, BC – April 7, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.